| Name | Title | Contact Details |
|---|
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
Headquartered in Tucson, Arizona, HTG is focused on advancing precision medicine. The company`s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.
Stuart Therapeutics was established in 2017 for the development and commercialization of PolyCol, a versatile therapeutic platform that offers a unique tissue reparative approach to a variety of ophthalmic disease indications.
Elysium`s mission is to solve the biggest challenges in health with science, to help people live healthier, longer lives. Working directly with the world`s leading scientists and clinicians, Elysium translates advances in science and technology into effective, scientifically sound health products that work.
Abivax is developing therapies that modulate the body`s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body`s natural immune system mechanisms to treat diseases.